Clinical Outcomes Research
Our unique position in the outpatient infusion management setting, in collaboration with our physician partners, gives us unprecedented access to the highest quality real-world clinical data.
Our data warehouse is the largest in the outpatient infusion industry
Our data sets go way beyond simple claims data and provide evidence-based research in areas such as drug utilization, clinical outcomes and disease response, safety, health economic impacts, and persistence. The strength of our data allows us to collaborate with manufacturers and physicians to study novel therapies, compare treatment sites, and other cutting-edge research.
Clinical Outcomes
Cost Savings & Lower Resource Utilization
New Therapies and Programs
Persistance
Special Populations
Here is an example of one of our class-leading studies enabled by our data:
Click image to view full size
Infection Incidence and Utilization of Antimicrobials in Physician Office Infusion Centers (POICs)
Lucinda J. Van Anglen, PharmD - Healix Infusion Therapy, Sugar Land, TX Thomas C. Hardin, PharmD - Healix Infusion Therapy, Sugar Land, TX Claudia P. Schroeder, PharmD, PhD - Healix Infusion Therapy, Sugar Land, TX View Poster
Effectiveness of A Community-based Inflammatory Bowel Disease Medical Home Compared to Patients not in a Medical Home
Presented at ACG 2024 Authors: Erica Cohen, MD Timothy E. Ritter, MD Lucinda J. Van Anglen, BS, PharmD Fiza Z. Baloch Kristen Attiogbe Precious Anyanwu, PharmD, PhD Brooke Hodnick Justin G. Kweit, BS Tyler Varisco, PharmD, PhD View Poster View...
Real-world Effectiveness and Onset of Action of Vedolizumab as a First-line Biologic in Biologic-Naïve Patients With Ulcerative Colitis
Presented at ACG 2024 Authors: Precious A Anyanwu Lucinda J Van Anglen Chiahung Chou Marie Sanchirico Timothy E Ritter View Poster View...
Immune Globulin Subcutaneous 16.5% in Treatment of Primary Immunodeficiency: A Two-Year, Multi-Center Analysis
Presented at IgNS 2024 Authors: Lucinda J. Van Anglen, PharmD Miren Patel, PharmD Christina J. Weeks, PharmD Richard F. Herrscher, MD, FACAAI Jeffrey W. Langford, MD, AE-C Precious A. Anyanwu, PharmD, PhD View...
Telavancin Outcomes in Infections Treated with Outpatient Parenteral Antibiotic Therapy (OPAT)
Presented at IDWeek 2024 Authors: Brian S. Metzger, MD, MPH Nikhil Bhayani, MD,FIDSA Thomas K. Sleweon, MD Rishi Bhattacharyya, MD Richard L. Hengel MD Kimberly A. Couch, PharmD Theresa L. Human, PharmD Emily A. Durr, PharmD Jason M. Makii, PharmD Lucinda J. Van...
Optimal Vancomycin Model Selection for Obese Patients Receiving Outpatient Parenteral Antimicrobial Therapy (OPAT)
Presented at IDWeek 2024 Authors: Kimberly A. Couch, PharmD, MA, FIDSA, FASHP Quyen Luu, MD Richard C. Prokesch, MD, FACP, FIDSA John S. Adams, MD, FIDSA, FSHEA Joseph F. John, Jr., MD, FACP, FIDSA Lucinda J. Van Anglen, BS, PharmD, FIDSA View...
Real-World Effectiveness of Fecal Microbiota, live-jslm for the Prevention of Recurrent Clostridioides difficile Infection
Presented at IDWeek 2024 Authors: Richard L. Hengel, MD Sujatha Krishan, MD Timothy E. Ritter, MD Jonathan A. Rosenberg, MD Kathy A. Baker Ph.D., APRN Lucinda J. Van Anglen, PharmD Kelly E. Hanna, PharmD Amy Guo, PhD Mielad Moosapanah, PharmD Sanghyuk Seo, PharmD,...
Infectious Disease Physician Office-Based HIV Program Results in Successful Adherence of Therapy in Patients Receiving Long-Acting Cabotegravir and Rilpivirine
Presented at IDWeek 2024 Authors: Nikhil K. Bhayani, MD, FIDSA Jorge R. Bernett, MD Thomas K. Sleweon, MD Erika M. Young, DO Kent J. Stock, DO Stacey E. Baker, MD Quyen Luu, MD Brian S. Metzger, MD, MPH Kimberly A. Couch, PharmD, MA, FIDSA, FASHP Christina J....
Biologic Therapy Sequencing in Ulcerative Colitis: A Real-World Observational Study of Second-Line Therapy After Vedolizumab
Presented at DDW 2024 Authors: Precious A. Anyanwu Christopher Fernandes Lucinda J. Van Anglen Chiahung Chou Marie Sanchirico Harry Sarles Casey Chapman Jeanne Jiang Tao Fan Lisa Young Timothy E. Ritter View...
Real World Outcomes of a Novel Fecal Microbiome Replacement Treatment for the Prevention of Recurrent Clostridioides Difficile Infection: A Multicenter Study
Presented at DDW 2024 Authors: Timothy E. Ritter, MD Jonathan A. Rosenberg, MD Richard L. Hengel, MD Sujatha Krishnan, MD Kathy A. Baker, PhD, APRN Lucinda J. Van Anglen, PharmD Kelly E. Hanna, PharmD Amy Guo, PhD Mielad Moosapanah, PharmD Kevin W. Garey, PharmD,...
Real World Experience of a Simple Administration of a Novel Fecal Microbiome Replacement for Prevention of Recurrent Clostridioides difficile
Presented at SGNA Annual Course 2024 Authors: Kathy A. Baker Ph.D., APRN Timothy E. Ritter, MD Jonathan A. Rosenberg, MD Richard L. Hengel MD Sujatha Krishan, MD Lucinda J. Van Anglen, BS, PharmD Kelly E. Hanna, PharmD Amy Guo, PhD Mielad Moosapanah, PharmD Kevin...
Real World Experience of a Simple Administration of a Novel Fecal Microbiome Replacement for Prevention of Recurrent Clostridioides difficile
Presented at MAD-ID 2024 Authors: Richard L. Hengel MD Sujatha Krishan, MD Timothy E. Ritter, MD Jonathan A. Rosenberg, MD Kathy A. Baker Ph.D., APRN Lucinda J. Van Anglen, BS, PharmD Kelly E. Hanna, PharmD Amy Guo, PhD Mielad Moosapanah, PharmD Sanghyuk Seo,...
Reductions in LDL-C within the First Year of Treatment with Inclisiran: Results from a Multicenter Real World Cohort
Presented at ACC 2024 Authors: Christie M. Ballantyne Tyler Varisco Timothy Graham Bruce J. Iteld Harvey Serota Sean McElligott Xiaoli Niu Kelly Hanna Lucinda Van Anglen View...
Phase II and Phase III Studies
Healix regularly and actively supports Phase II and Phase III clinical trials in each of our specialty areas, including active studies in Multiple Sclerosis and Intestinal Bowel Disease.
For information on partnering with Healix on a study, please contact us.